1. Гаврилова С.И. Фармакотерапия болезни Альцгеймера. М., 2003.
2. Дамулин И.В. Сосудистая деменция и болезнь Альцгеймера. М., 2002.
3. Левин О.С. Алгоритмы диагностики и лечения деменции. М., 2012.
4. Левин О.С. Деменция с тельцами Леви. М., 2006.
5. Одинак М.М., Литвиненко И.В., Емелин А.Ю. Открытое сравнительное исследование эффективности мемантина в терапии посттравматических когнитивных расстройств. Неврологич. журн. 2005; 6: 32–7.
6. Яхно Н.Н. Актуальные вопросы нейрогериатрии. В кн.: Достижения в нейрогериатрии. М., 1995; с. 9–27.
7. Aupperle PM, Tariot PN, Safirstein B et al. Long-term safety and efficacy of memantine treatment in moderate to severe Alzheimer’s disease. Eur J Neurology 2007; 14 (1): 1097.
8. Cummings JL, Frank JC, Cherry D et al. Guidelines for managing Alzheimer’s disease. Am Fam Physician 2002; 65: 2525–34.
9. Cummings JL. Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer’s disease. Neurology 2005; 65 (3): 18–24.
10. Cummings JL, Schneider E, Tariot P et al. Behavioral effects of memantine in Alzheimer’s disease patients receiving donepezil treatment. Neurology 2006; 67: 57–63.
11. Cummings JL, Grossberg G, Green P et al. Review of the safety and tolerability of treatment for moderate to severe AD. Eur J Neurology 2007; 14 (1): 1090.
12. Doody RS, Stevens JC, Beck RN et al. Practice parameter: management of dementia (an evidence-based review). Neurology 2001; 56: 1154–66.
13. Doody RS, Wirth Y, Schmitt F et al. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Dement Geritr Cogn Disord 2004; 18: 227–32.
14. Farlow MR, Cummings JL. Effective Pharmacologic Management of Alzheimer’s disease. Am J Med 2007; 120: 388–97.
15. Francis PT. Behavioral effects of memantine: understanding the pharmacological rationale. Eur J Neurology 2007; 14 (1): 2098.
16. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioral symptoms in Alzheimer disease patients. Int J Geriatr Psychiatry 2005; 20: 459–64.
17. Gauthier S (ed.). Clinical diagnosis and management of Alzheimer’s disease. London. Inf Health Care 2007.
18. Graham S, Resnick EM, Tocco M et al. Memantine is safe and effective in the treatment of moderate to severe Alzheimer’s disease: updated meta-analysis. Eur J Neurology 2007; 14 (1): 1096.
19. Li L, Sengupta A, Haque N et al. Memantine inhibits and reverses the Alzheimer’s type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters 2004; 566: 261–9.
20. Lyketos CG, Colenda CC, Beck C et al. Position statement of AAGP regarding principles of care for patients with dementia resulting from Alzheimer's disease. Am J Geriatr Psychiatry 2006; 14: 561–73.
21. Mendez MF, Cummings J. Dementia. Philadelphia, Butterworth Heinemann 2003.
22. Orgogozo JM, Rigaud AS, Stöffler A et al. Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300). Stroke 2002; 33: 1834–9.
23. Parsons CG, Danysz W, Quack G. Memantine is clinically well tolerated NMDA-receptor antagonist. Neuropharmacology 1999; 38: 735–67.
24. Petersen KA. Compliance and practical considerations in the management of Alzheimer’s disease with memantine. Eur J Neurology 2007; 14 (1): 1107.
25. Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer’s disease. Am J Geriatr Psychiatry 2006; 14: 704–15.
26. Reisberg B, Doody R, Stoffler A, Schmitt F et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41.
27. Reisberg B, Doody R, Stoffler A et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer’s disease. Arch Neurol 2006; 63: 49–54.
28. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of mementine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003; 9: 275–308.
29. Scharre DW. Galantamine with adjunctive memantine: combined effects on brain nicotinic acetylcholine receptors and NMDA receptors may improve Alzheimer’s disease symptomatology. J Clin Pharmacol 2006; 46: 6.
30. Schmidt R, Ropele S, Ebenbauer B et al. Memantine effects on brain volume, glucose metabolism and cognition in AD patients. Eur J Neurology 2007; 14 (1): 2526.
31. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer’s disease and other neurodegenerative disorders – memantine, a new hope. Pharmacol Research 2005; 51: 1–17.
32. Stoffler A, Wirth Y, Mobius HJ. Treatment of vascular dementia with memantine over one year. Eur J Neurology 2005; 12 (1): 2089.
33. Tariot PT, Farlow MR, Grossberg GR et al. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial JAMA 2004; 291: 317–24.
34. Tocco M, Resnick EM, Graham S et al. Cognitive effects of memantine in moderate to severe Alzheimer’s disease: a responder analysis. Eur J Neurology 2007; 14 (1): 1098.
35. Waldemar G, Dubois B, Emre M et al. Alzheimer’s disease and other disorders associated with dementia. R.Hughes et al. European handbook of neurological management. Oxford. Blackwell Publishing 2006; p. 266–98.
36. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 24: 138–45.
37. Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 2002; 17: 297–305.
38. Winblad B, Jones R, Wirth Y et al. Memantine in moderate to severe Alzheimer’s disease: meta-analysis of randomized clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20–7.

М.А.Аникина, Е.Е.Васенина, О.С.Левин 

Кафедра неврологии ГБОУ ДПО РМАПО, Москва